PodParley PodParley
PodParley
Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study episode artwork

EPISODE · Oct 11, 2024 · 4 MIN

Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study

from Medical Digest & Congress Report · host Medical Congress News

Professor Domenica Lorusso presented the overall survival results from the randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer. Video: https://medicaldigest.org/scientific-contents/interview:pembrolizumab-plus-chemoradiotherapy-high-risk-locally-advanced-cervical-cancer-overall-survival-results-randomized-double-blind-phase-3-engot-cx11gog-3047keynote-a18-study

Episode metadata supplied by the publisher feed · Published Oct 11, 2024

Embed this episode

NOW PLAYING

Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study

0:00 4:39

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 4 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on October 11, 2024.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!